-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Initiates Coverage On ArriVent BioPharma with Buy Rating, Announces Price Target of $45

Benzinga·12/10/2025 12:34:00
Listen to the news
BTIG analyst Justin Zelin initiates coverage on ArriVent BioPharma (NASDAQ:AVBP) with a Buy rating and announces Price Target of $45.